Sun Pharmaceutical Industries Limited — Sponsor Intelligence | 44 EU Trials

Filter these 44 trials by condition, phase, country and more.

Open in Search →

44 Registered trials

2 Recruiting

34 Completed trials

10 Countries active

4 Unique IMPs

100% Results reported

Other

Phase III: 4 Phase II/III: 1 Phase II: 3 Phase I (Other): 2 Other: 34

100%

34 of 34 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Axial spondyloarthritis 3 Crohn's disease 3 Colitis ulcerative 3

Top IMPs

TILDRAKIZUMAB 4 VIBOZILIMOD 2 ETANERCEPT 1 UTREGLUTIDE 1

All trials — page 2

44 total

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ruxolit… Ended

2024-519801-36-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Naltrex… Ended

2024-519776-20-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutam… Ended

2024-518209-16-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutam… Ended

2024-518211-20-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivara… Ended

2024-516500-42-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Bosutinib… Ended

2024-516489-12-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Dextroa… Ended

2023-509874-48-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigi… Ended

2024-513106-62-00 1 country
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Empagli… Ended

2024-513340-28-00 1 country
An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioeq… Ended

2024-512770-10-00 1 country
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadaci… Ended

2024-512771-12-00 1 country
A Phase 2 Parallel Group Study in Adults with Type 2 Diabetes to evaluate Efficacy and Safety of GL0034 Ended

2024-513279-41-00 Phase II 1 country UTREGLUTIDE
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadaci… Ended

2024-512773-27-00 1 country
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosam… Ended

2023-507991-32-00 1 country
A phase IIb study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis Ended

2023-506477-35-00 Phase II 2 countries VIBOZILIMOD
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Ivacaft… Ended

2023-508115-23-00 1 country
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Dapagli… Ended

2023-506408-18-00 1 country
To access the effect of SCD-044 in treatment of moderate to severe atopic dermatitis Ended

2024-511615-16-00 Phase II 2 countries VIBOZILIMOD
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Su… Ended

2024-512142-42-00 Phase III 4 countries TILDRAKIZUMAB
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien… Ended

2023-507415-35-00 Phase III 7 countries TILDRAKIZUMAB

Showing 25–44 of 44 trials

← All sponsors A–Z